AbbVie's Skyrizi and Rinvoq offset Humira decline
Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash
AbbVie's next-generation immunology drugs, Skyrizi and Rinvoq, are offsetting the decline of legacy blockbuster Humira, demonstrating the company's ability to manage patent cliffs. The transition spans a diversified portfolio including oncology, neuroscience and aesthetics. Strong performance of the newer drugs drove raised full-year earnings guidance.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.